Vascular graft or vascular bypass is a surgical procedure performed to bypass a diseased artery by redirecting blood from an area of normal blood flow to another relatively normal area. There are different vascular grafts based on the indication and raw materials used for the graft to suit the host tissue. Vascular grafts are used for hemodialysis vascular access and endovascular aneurysm & thoracic aneurysm repair.

The vascular grafts market is projected to reach USD 3.80 billion by 2022 from USD 2.67 billion in 2017, at a CAGR of 7.3%. The major factors driving the growth of this market are the high burden of abdominal aneurysms, increasing geriatric population, and increasing prevalence of smoking & other risk factors that promote aneurysm.

�By raw material, the polyester grafts segment to hold the largest market share during the forecast period.�

The polyester grafts segment is expected to hold the largest market share, mainly due to the high use of this material in vascular grafts and its long lifespan. This segment is also estimated to register the highest CAGR during the forecast period.

�By indication, the endovascular aneurysm repair segment to record the highest CAGR and to retain the largest share in the market.�

The growth of this segment is mainly driven by the rising adoption of endovascular aneurysm repair surgical procedures, increasing preference for minimally invasive surgical procedures over open surgeries, and growing geriatric population.

�By end-user, the hospitals segment is expected to grow at the highest CAGR during the forecast period.�

The hospitals segment is expected to grow at the highest CAGR during the forecasted period. The high growth of this segment is attributed to factors such as the rising number of minimally invasive surgical procedures in hospitals & cardiac centers and the favorable reimbursement scenario in most developed countries.

�APAC to lead the global vascular grafts market during the forecast period.�

The increasing growth of the Asia Pacific market can be attributed to the rising prevalence of CKD, healthcare reforms, government initiatives and investments, and rapid growth in the geriatric population. Also, emerging markets, such as Australia, Singapore, Japan, and China, offer numerous growth opportunities for players operating in the vascular grafts market due to the increasing geriatric population, increasing end-stage renal disorders.

Market Dynamics

Driver: Increasing incidence of ESRD

According to the University of California, approximately 2 million people worldwide suffer from ESRD. Annually, ESRD affects around 650,000 people in the US. Japan, Taiwan, Mexico, the US, and Belgium currently have the highest prevalence of ESRD.

The only alternative to kidney transplantation is dialysis, which is frequently used by patients with ESRD. Hemodialysis treatment is done three times per week. Because of prolonged dialysis, the superficial veins of many patients are exhausted, and vascular grafts remain the only option to allow continued hemodialysis.

Also, according to the National Institute of Diabetes and Digestive and Kidney Diseases (2016), the overall prevalence of CKD in the US is ~14%. More than 0.6 million Americans have kidney failure. Of these, 0.4 million individuals are on dialysis.

Restraint: Product failures and recalls

Product failures can have severe or even lethal complications in patients. Over the years, several products offered by companies have been recalled from the market due to product malfunctions or other issues. Market developments can hurt the end-user perception of the safety of grafts and, in turn, affect their adoption in treatment procedures.

Opportunity : Emerging markets

Emerging markets, such as Australia, Singapore, Japan, and China, offer significant growth opportunities for players operating in the vascular grafts market. According to the NCBI, in Japan, between 2007and 2015, 985 out of 999 patients who underwent EVAR were older than 50 years. As Japan has the highest proportion of geriatric individuals, an increase in this population segment will result in the increasing incidence of aortic aneurysms. According to 2014 estimates of the Ministry of Internal Affairs and Communication, 33.0% of the Japanese population is above the age of 60. By 2050, it is expected that 40% of Japan�s population will be over 65.

These markets are expected to witness high growth in the coming years owing to their comparatively lenient regulatory policies and the increasing burden of aneurysms. This has prompted major players to expand their geographic reach to emerging markets. For instance, in May 2016, Medtronic Inc. (US) opened its Asia Pacific regional headquarters in Singapore to support and strengthen its operations in 80 locations across the Asia Pacific.

Scope of the Report

Report Metric Details Market size available for years 2015�2022 Base year considered 2016 Forecast period 2017�2022 Forecast units USD million Segments covered Raw Material, Indication, End User, and Region Geographies covered North America, Europe, APAC, and Rest of the World (RoW) Companies covered B. Braun (Germany), C. R. Bard (US), Cardinal Health (US), Cook Medical (US), Endologix (US), LeMaitre Vascular (US), Medtronic (Ireland), Maquet (Germany), Terumo (Japan), and Gore Medical (US)

This report categorizes the market into the following segments:

Vascular Graft Market by Raw Material

Polyester Grafts

ePTFE

Polyurethane Grafts

Biosynthetic Grafts

Vascular Graft Market by Indication

Endovascular Aneurysm Repair Abdominal Aortic Aneurysms Repair Thoracic Aortic Aneurysm Repair

Peripheral Vascular

Hemodialysis Access

Vascular Graft Market by End User

Hospitals

Ambulatory Surgical Centers

Vascular Graft Market by Region

North America US Canada

Europe UK Germany France Italy Rest of Europe

Asia Pacific China Australia Japan India Rest of APAC

Rest of the World

Key Market Players

Medtronic (Ireland), B. Braun (Germany), Endologix (US), Terumo (Japan), C. R. Bard (US)

Recent Developments

In October 2017, Medtronic received FDA approval for Medtronic Endurant II/IIs, a thoracic stent graft system, to use with the Heli-FX EndoAnchor system.

In April 2017, Endologix Inc. signed an agreement with Deerfield Management, a leading healthcare investment organization, to allot funding worth USD 170 million.

In January 2017, Endologix received reinstatement of the CE Mark for AFX and AFX 2 Endovascular AAA System.

Critical questions the report answers:

What are the upcoming trends for the vascular grafts market?

Which segment in the vascular grafts market provides the most opportunity for growth? Who are the leading vendors operating in the market?

What are the opportunities for new market entrants in the vascular grafts market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst